TY - JOUR
T1 - Optimal range of injection rates for a lymphatic drug delivery system
AU - Fujii, Honoka
AU - Horie, Sachiko
AU - Takeda, Kazu
AU - Mori, Shiro
AU - Kodama, Tetsuya
N1 - Funding Information:
The study was supported by Japan Society for the Promotion of Science KAKENHI grant numbers 16K15816 (S.M.), 17K20077 (T.K.) and 17H00865 (T.K.). The authors would like to thank T. Sato for excellent technical assistance.
Publisher Copyright:
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
PY - 2018/8
Y1 - 2018/8
N2 - The lymphatic drug delivery system (LDDS) is a new technique that permits the injection of drugs into a sentinel lymph node (SLN) at an early stage of tumor metastasis, thereby treating metastasis in the SLN and its secondary lymph nodes (LNs). The quantity of drug required for a LDDS is much smaller than that needed for systemic chemotherapy. However, the relationship between the rate of drug injection into a SLN and the amount of drug reaching the secondary LNs has not been investigated. In this study, we used an MXH10/Mo-lpr/lpr mouse model to show that the optimal rate for the injection of a fluorescent dye by a LDDS was 10 to 80 μL/min. An injection rate of 10 to 80 μL/min was able to fill the downstream LN. However, an injection rate of 100 μL/min drove the fluorescent dye into the efferent lymphatic vessels and thoracoepigastric vein, decreasing the amount of dye retained in the downstream LN. Bolus injection (defined as an injection rate of 2400 μL/min) was unable to deliver fluorescent dye into the downstream LN. These results agree with the impulse values calculated from the injection pressures in the upstream LN. We anticipate that our findings will facilitate the development of a LDDS for use in the clinic.
AB - The lymphatic drug delivery system (LDDS) is a new technique that permits the injection of drugs into a sentinel lymph node (SLN) at an early stage of tumor metastasis, thereby treating metastasis in the SLN and its secondary lymph nodes (LNs). The quantity of drug required for a LDDS is much smaller than that needed for systemic chemotherapy. However, the relationship between the rate of drug injection into a SLN and the amount of drug reaching the secondary LNs has not been investigated. In this study, we used an MXH10/Mo-lpr/lpr mouse model to show that the optimal rate for the injection of a fluorescent dye by a LDDS was 10 to 80 μL/min. An injection rate of 10 to 80 μL/min was able to fill the downstream LN. However, an injection rate of 100 μL/min drove the fluorescent dye into the efferent lymphatic vessels and thoracoepigastric vein, decreasing the amount of dye retained in the downstream LN. Bolus injection (defined as an injection rate of 2400 μL/min) was unable to deliver fluorescent dye into the downstream LN. These results agree with the impulse values calculated from the injection pressures in the upstream LN. We anticipate that our findings will facilitate the development of a LDDS for use in the clinic.
KW - MXH10/Mo-lpr/lpr mice
KW - injection rate
KW - lymph node metastasis
KW - lymphatic drug delivery system (LDDS)
KW - lymphatic network
UR - http://www.scopus.com/inward/record.url?scp=85044944566&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044944566&partnerID=8YFLogxK
U2 - 10.1002/jbio.201700401
DO - 10.1002/jbio.201700401
M3 - Article
C2 - 29461015
AN - SCOPUS:85044944566
SN - 1864-063X
VL - 11
JO - Journal of Biophotonics
JF - Journal of Biophotonics
IS - 8
M1 - e201700401
ER -